LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Stock May Be 37% Undervalued Despite Lung Cancer Trial News
AstraZeneca stock has delivered a 5 year return of 88.1%, and today the valuation debate centers on whether that past run is still supported by what the intrinsic value and market multiples are implying, especially as recent oncology and rare disease news keeps attention on its pipeline.
Over the past 5 years, AstraZeneca has returned 88.1%, which puts more focus on whether the current price still offers a margin between market value and intrinsic value.
New developments around therapies...